30 reports of this reaction
2.9% of all FERROSOFERRIC PHOSPHATE reports
#3 most reported adverse reaction
HEADACHE is the #3 most commonly reported adverse reaction for FERROSOFERRIC PHOSPHATE, manufactured by DNA Labs. There are 30 FDA adverse event reports linking FERROSOFERRIC PHOSPHATE to HEADACHE. This represents approximately 2.9% of all 1,043 adverse event reports for this drug.
Patients taking FERROSOFERRIC PHOSPHATE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for FERROSOFERRIC PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for FERROSOFERRIC PHOSPHATE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 30 FDA reports for FERROSOFERRIC PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.9% of all adverse event reports for FERROSOFERRIC PHOSPHATE, making it one of the most commonly reported side effect.
If you experience headache while taking FERROSOFERRIC PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.